Early weakness (shares have since recovered) in Sarepta Therapeutics (SRPT +1.4%) is being...

Early weakness (shares have since recovered) in Sarepta Therapeutics (SRPT +1.4%) is being attributed at least in part to Deutsche's Robyn Karnauskas, who has some questions about Eteplirsen. Specifically, the analyst says FDA draft guidelines suggest a Breakthrough designation for the DMD treatment could be withdrawn if "another drug in same indication gains approval." The worry is that Prosensa's Drisapersen gets to market first. However, Karnauskas does think Eteplirsen has a "substantial safety advantage." (Also: Piper likes SRPT's DMD chances)

From other sites
Comments (1)
  • ravenben
    , contributor
    Comments (23) | Send Message
    Hmm, it's somewhat difficult to take this note seriously, because
    1) Robyn misspells Sarepta (as Serepta)
    2) Far more importantly, SRPT never applied for breakthrough designation! Breakthrough has different requirements than AA, and this note has no bearing on SRPT's AA probability, period.
    26 Jun 2013, 12:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs